FB

Frank Bruchertseifer

3 records found

Authored

Background: The [177Lu]Lu-DOTA-TATE mediated peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) is sometimes leading to treatment resistance and disease recurrence. An interesting alternative could be the somatostatin antagonist, [177< ...

Increasing attention is given to personalized tumour therapy, where α-emitters can potentially play an important role. Alpha particles are ideal for localized cell killing because of their high linear energy transfer and short ranges. However, upon the emission of an α particl ...

The combined α-, γ-, and x-ray emitter 213Bi (half-life, 46 min) is promising for radionuclide therapy. SPECT imaging of 213Bi is challenging, because most emitted photons have a much higher energy (440 keV) than common in SPECT. We assessed 213